Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Non-interventional Post-authorization Study of Belzutifan in Adult Patients With Von Hippel-Lindau Disease-associated Renal Cell Carcinoma, Pancreatic Neuroendocrine Tumor and/or Central Nervous System Hemangioblastoma (MK-6482-026)

Next Previous
X
Search
Trial Profile

Non-interventional Post-authorization Study of Belzutifan in Adult Patients With Von Hippel-Lindau Disease-associated Renal Cell Carcinoma, Pancreatic Neuroendocrine Tumor and/or Central Nervous System Hemangioblastoma (MK-6482-026)

Status: Withdrawn prior to enrolment
Phase of Trial: Phase IV

Latest Information Update: 02 Dec 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Belzutifan (Primary)
  • Indications Haemangioblastoma; Neuroendocrine tumours; Pancreatic cancer; Renal cell carcinoma; Von Hippel-Lindau disease
  • Focus Therapeutic Use
  • Sponsors Merck Sharp & Dohme

    • Most Recent Events

    • 28 Nov 2024 Status changed from not yet recruiting to withdrawn prior to enrolment. (Study is registered /active on RWD Catalogues (https://catalogues.ema.europa.eu) - Please refer to EU PAS number: EUPAS108114 )
    • 28 Nov 2024 Planned End Date changed from 13 May 2029 to 31 Dec 2030.
    • 28 Nov 2024 Planned primary completion date changed from 13 May 2027 to 31 Dec 2030.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top